Dr. Stephen Paul Lucero, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1650 Hospital Dr, Suite 300, Santa Fe, NM 87505 Phone: 505-989-8325 Fax: 505-982-7665 |
Steven Craig Robeson, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1630 Hospital Dr, Suite C, Santa Fe, NM 87505 Phone: 505-982-3534 Fax: 505-982-8458 |
Michael Milroy, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1630 Hospital Dr, Suite B, Santa Fe, NM 87505 Phone: 505-820-0484 Fax: 505-820-6138 |
Dr. Eric William Anderson, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1630 Hospital Dr, Suite D, Santa Fe, NM 87505 Phone: 505-982-3534 Fax: 505-982-8458 |
Margaret N Le, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 4801 Beckner Rd Ste 1700, Santa Fe, NM 87507 Phone: 505-772-2000 |
News Archive
A team led by Massachusetts General Hospital researchers has identified a genetic signature that appears to reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer.
Although not all Republican governors are pushing to change Medicaid into a block-grant program, there seems to be general agreement for seeking greater flexibility in how states spend Medicaid dollars. Reports also persist that some Democratic lawmakers appear open to plans to chip away at Medicaid's requirements.
In recent years, the biopharmaceutical industry has seen an explosion in the availability of Big Data that can generate valuable insights. Despite this, the inherent costs and challenges that come with utilizing Big Data have caused the biopharmaceutical sector to embrace Big Data analytics much slower than other industries.
Study investigators today reported initial data from Cook Medical's REFORM clinical trial that is aimed at assessing the safety and effectiveness of the company's balloon-expandable renal stent for the treatment of renal artery stenosis. The data, presented by Robert Bersin, M.D., at ISET 2011, reveal a nine-month primary patency rate of 89.5 percent and a 97 percent rate of successful delivery and deployment of the stent.
› Verified 4 days ago